Developer docs
API playgroundTry for free, no card

Search company profiles

GI Dynamics

Full company profile

uuid00062mj

Namestring
GI Dynamics
Legal namestring
Morphic Medical, Inc.
Websiteurl
gidynamics.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

GI Dynamics (operating publicly as Morphic Medical, Inc.) is a medical device company founded in 2003 that develops RESET®, an endoscopically delivered device therapy intended to reduce HbA1c and weight in patients with type 2 diabetes and obesity. RESET® is positioned to bridge the gap between pharmaceutical therapy and bariatric surgery by serving patients whose disease is not adequately controlled by drugs and injections but for whom surgery is not appropriate. The underlying technology is a minimally invasive, endoscopically implanted device that the company describes as the first of its kind to target the underlying cause of type 2 diabetes; supporting assets include a registered RESET® trademark and an actively maintained patents portfolio.

The company's business model is hardware sales of the RESET® device to hospitals and outpatient endoscopy centers. Commercial sales are currently authorized only in the European Union and the United Kingdom, with a separate EU website (eu.morphicmedical.com) and regional channel partners supporting distribution. In the United States, RESET® is limited to Investigational Use, and access is restricted to enrollment in the STEP-1 clinical study via StudyType2Diabetes.com. Pricing is not publicly disclosed and is quote-based. The company employs 51-100 staff and is led by Chairman Mark Lerdal, CFO Robert Crane, and VP of Clinical and Regulatory Affairs Steve Linhares.

Cumulatively, the company has raised over $200M across 13 funding rounds from 2003 through 2019, including a $15M strategic investment by Medtronic in 2010 and a $10M round led by Crystal Amber in 2019. The firm was previously listed on the ASX under ticker GID (now delisted) and is now headquartered in Boston, Massachusetts. The company markets itself primarily through clinical evidence, conference presence (e.g., EASD 2022), earned media (including BBC News coverage), and clinical publications rather than consumer advertising, consistent with a specialist, clinical-led go-to-market motion.

Short descriptiontext

GI Dynamics (operating as Morphic Medical) develops RESET®, an endoscopically delivered device therapy for type 2 diabetes and obesity. The device is commercially available in the EU and UK and under U.S. clinical investigation via the STEP-1 trial, sold to specialist hospitals and endoscopy centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes treatment devices, endoscopic medical devices, metabolic disease therapy, obesity treatment devices, bariatric device alternatives
Industry3 codes
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKADAC
Type 2 Diabetes Care
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Computer Systems Design Services541512
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Diabetes and Obesity Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (RESET®)
TypeHardware Sales
Description

Revenue generated from sale of the RESET® endoscopic device to hospitals and endoscopy centers. Commercial sales currently authorized in the EU and UK; U.S. revenue limited to investigational use. Pricing not publicly disclosed.

morphicmedical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1RESET®
Description

World's first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity, designed to bridge the gap between pharmaceuticals and surgery.

morphicmedical.com
Core offering1 text field

GI Dynamics develops and commercializes RESET®, an endoscopically delivered medical device therapy for the treatment of type 2 diabetes and obesity. RESET® is positioned as the first device of its kind designed to target the underlying cause of type 2 diabetes and to bridge the gap between pharmaceutical therapy and bariatric surgery by reducing HbA1c and weight in patients underserved by drugs and injections. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where enrollment in the STEP-1 clinical study is ongoing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Targets reduction of HbA1c and weight in type 2 diabetes and obesity patients underserved by drugs/injections and ineligible for surgery
+1 more record
Product overview1 text field

The provided source material does not describe any GI Dynamics products or services. The news article discusses the broader bariatric surgery devices market, referencing Duomed Group's acquisition of REY Médical SA and Johnson & Johnson MedTech's launch of the ECHELON ENDOPATH staple line reinforcement device, but does not mention any GI Dynamics offering. The webpage describes Morphic Medical's RESET® therapy for type 2 diabetes, which is a Morphic Medical product rather than a GI Dynamics product based on the source text.

Product and service1 record
1RESET® Therapy
CategoryEndoscopic diabetes and obesity treatment device
Description

RESET® is the first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. It is intended to reduce HbA1c and weight in patients whose type 2 diabetes and weight are not adequately controlled by drugs and injections but for whom bariatric surgery is not an appropriate option. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where it is being evaluated in the STEP-1 clinical study.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-01
Description

Not a direct partnership with the subject company; referenced in source news as a competitive/distribution signal in the bariatric surgery devices market. In July 2024, Belgium-based Duomed Group acquired Swiss distributor REY Médical SA to expand its distribution network in Switzerland for minimally invasive surgical equipment. Included as market-context signal for the broader category in which the subject company competes.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fractyl Health develops Revita DMR, an endoscopic duodenal mucosal resurfacing procedure for type 2 diabetes — the most direct mechanistic and clinical competitor to RESET® in the endoscopic T2D device category, targeting the same treatment-gap patient population.

TypeDirect peer
Description

Apollo Endosurgery markets endoscopic bariatric/metabolic devices including the Orbera intragastric balloon and OverStitch endoscopic suturing system, competing with RESET® for the same endoscopist channel and obesity-with-comorbid-T2D patient segment.

TypeDirect peer
Description

USGI Medical develops endoscopic tissue approximation and bariatric/metabolic devices (e.g., g-Cath EZ Suture System), operating in the same endoscopic bariatric/metabolic procedure category as RESET® and targeting similar specialist physician channels.

TypeDirect peer
Description

Allurion markets the Allurion Gastric Balloon, a procedureless (swallowable) endoscopic weight-loss device, competing with RESET® for endoscopy-center adoption and the obesity/metabolic disease patient segment.

TypeDirect peer
Description

ReShape Lifesciences markets the LAP-BAND system and previously the ReShape intragastric balloon, positioning itself as an endoscopic/surgical obesity-device competitor to RESET® for patients with obesity and metabolic comorbidities.

TypeEmerging player
Description

Spatz3 is an adjustable endoscopic intragastric balloon competing in the endoscopic bariatric space alongside RESET®'s obesity indication, with overlapping specialist-channel dynamics but a more niche commercial footprint.

TypeEmerging player
Description

Aspire Bariatrics developed the AspireAssist aspiration therapy, a percutaneous/endoscopic weight-loss device positioned between pharmacotherapy and bariatric surgery in a similar treatment-gap niche to RESET®.

TypeBroad incumbent
Description

Medtronic is a historical GI Dynamics investor (2010, $15M) and a dominant bariatric/metabolic medtech incumbent with surgical stapling, hernia, and obesity-intervention portfolios, making it both a strategic channel partner and a potential acquirer.

TypeBroad incumbent
Description

J&J MedTech (through J&J Development Corporation as a 2009 investor in GI Dynamics) operates a broad minimally invasive and bariatric surgery portfolio (e.g., ECHELON ENDOPATH), positioning it as a strategic acquirer and incumbent in the same end-procedure category.

TypeOthers
Description

Novo Nordisk markets Ozempic, Wegovy, and Rybelsus (GLP-1 agonists) — the principal pharmacologic competitor shaping the T2D/obesity treatment landscape that RESET® must position against as a non-pharmacologic device alternative.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GI Dynamics

Diabetes and Obesity Medical Devicesgidynamics.com

GI Dynamics (operating as Morphic Medical) develops RESET®, an endoscopically delivered device therapy for type 2 diabetes and obesity. The device is commercially available in the EU and UK and under U.S. clinical investigation via the STEP-1 trial, sold to specialist hospitals and endoscopy centers.

What GI Dynamics does

GI Dynamics (operating publicly as Morphic Medical, Inc.) is a medical device company founded in 2003 that develops RESET®, an endoscopically delivered device therapy intended to reduce HbA1c and weight in patients with type 2 diabetes and obesity. RESET® is positioned to bridge the gap between pharmaceutical therapy and bariatric surgery by serving patients whose disease is not adequately controlled by drugs and injections but for whom surgery is not appropriate. The underlying technology is a minimally invasive, endoscopically implanted device that the company describes as the first of its kind to target the underlying cause of type 2 diabetes; supporting assets include a registered RESET® trademark and an actively maintained patents portfolio.

The company's business model is hardware sales of the RESET® device to hospitals and outpatient endoscopy centers. Commercial sales are currently authorized only in the European Union and the United Kingdom, with a separate EU website (eu.morphicmedical.com) and regional channel partners supporting distribution. In the United States, RESET® is limited to Investigational Use, and access is restricted to enrollment in the STEP-1 clinical study via StudyType2Diabetes.com. Pricing is not publicly disclosed and is quote-based. The company employs 51-100 staff and is led by Chairman Mark Lerdal, CFO Robert Crane, and VP of Clinical and Regulatory Affairs Steve Linhares.

Cumulatively, the company has raised over $200M across 13 funding rounds from 2003 through 2019, including a $15M strategic investment by Medtronic in 2010 and a $10M round led by Crystal Amber in 2019. The firm was previously listed on the ASX under ticker GID (now delisted) and is now headquartered in Boston, Massachusetts. The company markets itself primarily through clinical evidence, conference presence (e.g., EASD 2022), earned media (including BBC News coverage), and clinical publications rather than consumer advertising, consistent with a specialist, clinical-led go-to-market motion.

GI Dynamics firmographics

Firmographics
Name
GI Dynamics
Legal name
Morphic Medical, Inc.
Website
https://gidynamics.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
GI Dynamics (operating as Morphic Medical) develops RESET®, an endoscopically delivered device therapy for type 2 diabetes and obesity. The device is commercially available in the EU and UK and under U.S. clinical investigation via the STEP-1 trial, sold to specialist hospitals and endoscopy centers.
Ownership category
akta.pro rank

GI Dynamics industry classification

Industry
Product category
Diabetes and Obesity Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Computer Systems Design Services (541512)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKADAC
Type 2 Diabetes Care

Keywords

  • Diabetes treatment devices
  • Endoscopic medical devices
  • Metabolic disease therapy
  • Obesity treatment devices
  • Bariatric device alternatives

Where GI Dynamics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GI Dynamics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Medical Device Sales (RESET®): Revenue generated from sale of the RESET® endoscopic device to hospitals and endoscopy centers. Commercial sales currently authorized in the EU and UK; U.S. revenue limited to investigational use. Pricing not publicly disclosed.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

GI Dynamics product offering

Product offering

Core offering

GI Dynamics develops and commercializes RESET®, an endoscopically delivered medical device therapy for the treatment of type 2 diabetes and obesity. RESET® is positioned as the first device of its kind designed to target the underlying cause of type 2 diabetes and to bridge the gap between pharmaceutical therapy and bariatric surgery by reducing HbA1c and weight in patients underserved by drugs and injections. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where enrollment in the STEP-1 clinical study is ongoing.

Product overview

The provided source material does not describe any GI Dynamics products or services. The news article discusses the broader bariatric surgery devices market, referencing Duomed Group's acquisition of REY Médical SA and Johnson & Johnson MedTech's launch of the ECHELON ENDOPATH staple line reinforcement device, but does not mention any GI Dynamics offering. The webpage describes Morphic Medical's RESET® therapy for type 2 diabetes, which is a Morphic Medical product rather than a GI Dynamics product based on the source text.

Differentiator

Problem solved

Functional benefit

Brands

  • RESET®: World's first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity, designed to bridge the gap between pharmaceuticals and surgery.

Products and services

  • RESET® Therapy RESET® is the first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. It is intended to reduce HbA1c and weight in patients whose type 2 diabetes and weight are not adequately controlled by drugs and injections but for whom bariatric surgery is not an appropriate option. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where it is being evaluated in the STEP-1 clinical study.

Quantifiable outcome

  • Targets reduction of HbA1c and weight in type 2 diabetes and obesity patients underserved by drugs/injections and ineligible for surgery
  • +1 more outcomes

Companies that use GI Dynamics

Customer profile

Segments3 records

Ideal customer profiles2 records

GI Dynamics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

GI Dynamics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Duomed Group / REY Médical SAminorChannel Partner/ Reseller/ Distributor · 1 July 2024Not a direct partnership with the subject company; referenced in source news as a competitive/distribution signal in the bariatric surgery devices market. In July 2024, Belgium-based Duomed Group acquired Swiss distributor REY Médical SA to expand its distribution network in Switzerland for minimally invasive surgical equipment. Included as market-context signal for the broader category in which the subject company competes.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

GI Dynamics competitors and assessment

Company assessment

Direct peers

  • Fractyl Health: Fractyl Health develops Revita DMR, an endoscopic duodenal mucosal resurfacing procedure for type 2 diabetes — the most direct mechanistic and clinical competitor to RESET® in the endoscopic T2D device category, targeting the same treatment-gap patient population.
  • Apollo Endosurgery: Apollo Endosurgery markets endoscopic bariatric/metabolic devices including the Orbera intragastric balloon and OverStitch endoscopic suturing system, competing with RESET® for the same endoscopist channel and obesity-with-comorbid-T2D patient segment.
  • USGI Medical: USGI Medical develops endoscopic tissue approximation and bariatric/metabolic devices (e.g., g-Cath EZ Suture System), operating in the same endoscopic bariatric/metabolic procedure category as RESET® and targeting similar specialist physician channels.
  • Allurion Technologies: Allurion markets the Allurion Gastric Balloon, a procedureless (swallowable) endoscopic weight-loss device, competing with RESET® for endoscopy-center adoption and the obesity/metabolic disease patient segment.
  • ReShape Lifesciences: ReShape Lifesciences markets the LAP-BAND system and previously the ReShape intragastric balloon, positioning itself as an endoscopic/surgical obesity-device competitor to RESET® for patients with obesity and metabolic comorbidities.

Emerging players

  • Spatz FGIA (Spatz Medical): Spatz3 is an adjustable endoscopic intragastric balloon competing in the endoscopic bariatric space alongside RESET®'s obesity indication, with overlapping specialist-channel dynamics but a more niche commercial footprint.
  • Aspire Bariatrics: Aspire Bariatrics developed the AspireAssist aspiration therapy, a percutaneous/endoscopic weight-loss device positioned between pharmacotherapy and bariatric surgery in a similar treatment-gap niche to RESET®.

Broad incumbents

  • Medtronic: Medtronic is a historical GI Dynamics investor (2010, $15M) and a dominant bariatric/metabolic medtech incumbent with surgical stapling, hernia, and obesity-intervention portfolios, making it both a strategic channel partner and a potential acquirer.
  • Johnson & Johnson MedTech: J&J MedTech (through J&J Development Corporation as a 2009 investor in GI Dynamics) operates a broad minimally invasive and bariatric surgery portfolio (e.g., ECHELON ENDOPATH), positioning it as a strategic acquirer and incumbent in the same end-procedure category.

Others

  • Novo Nordisk: Novo Nordisk markets Ozempic, Wegovy, and Rybelsus (GLP-1 agonists) — the principal pharmacologic competitor shaping the T2D/obesity treatment landscape that RESET® must position against as a non-pharmacologic device alternative.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

GI Dynamics social profiles

Digital presence

GI Dynamics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GI Dynamics leadership team

Management profile

Number of profiles

Profiles3 records

GI Dynamics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GI Dynamics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GI Dynamics

What does GI Dynamics do?

GI Dynamics develops and commercializes RESET®, an endoscopically delivered medical device therapy for the treatment of type 2 diabetes and obesity. RESET® is positioned as the first device of its kind designed to target the underlying cause of type 2 diabetes and to bridge the gap between pharmaceutical therapy and bariatric surgery by reducing HbA1c and weight in patients underserved by drugs and injections. The device is approved for sale in the EU and UK and is limited to Investigational Use in the United States, where enrollment in the STEP-1 clinical study is ongoing.

Is GI Dynamics a public or private company?

GI Dynamics is a private company. It is classified as venture growth investor backed and is currently operating.

When was GI Dynamics founded?

GI Dynamics was founded in 2003. It employs 11 to 50 people.

Where is GI Dynamics based?

GI Dynamics is headquartered in Boston, United States, in the North America region.

How does GI Dynamics make money?

One revenue line is on record: medical Device Sales (RESET®).

Who are GI Dynamics's main competitors?

Direct peers on record are Fractyl Health, Apollo Endosurgery, USGI Medical, Allurion Technologies and ReShape Lifesciences. Emerging players are Spatz FGIA (Spatz Medical) and Aspire Bariatrics. Broad incumbents are Medtronic and Johnson & Johnson MedTech. Novo Nordisk is listed as an others.

Does GI Dynamics have an API?

No public API is recorded for GI Dynamics.

What industry is GI Dynamics in?

GI Dynamics's product category is Diabetes and Obesity Medical Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Michigan MedicineMinimally-Invasive, Innovative Therapy Used for Treating Type 2 Diabetes and ObesityGI Dynamics Inc. is enrolling patients in the STEP-1 clinical trial at the University of Michigan to evaluate its EndoBarrier device for treating type 2 diabetes and obesity. The pivotal study aims to assess whether this non-invasive endoscopic procedure can effectively reduce blood sugar levels (HbA1c) over a 12-month period compared to lifestyle therapies alone.PR NewswireGlobal Bariatric Surgery Devices Market Analysis & Trends Report 2016 - Forecasts to 2025 for the $3.8 Billion Industry - Research and MarketsResearch and Markets released a report on the global bariatric surgery devices market, forecasting growth to $3.84 billion by 2025 at a 9.7% CAGR. The study covers product segments, procedures, and major geographies, with historical data and forecasts through 2025.TodaysmedicaldevelopmentsGlobal bariatric surgery devices market worth $2.8B by 2022A report by Grand View Research Inc. projects the global bariatric surgery devices market will reach $2.8 billion by 2022, driven by rising obesity rates and a shift toward non-invasive procedures. Key market players such as Medtronic, GI Dynamics Inc., and Ethicon are actively innovating with new devices and conducting collaborative studies to address co-morbidities like diabetes.GlobeNewswireInitial Results of GI Dynamics's EndoBarrier Presented at American Diabetes Association ConferenceGI Dynamics presented initial results of its EndoBarrier device at the American Diabetes Association conference, showing rapid weight loss and Type 2 diabetes remission. In a trial, 12 patients with diabetes received the device, and most saw immediate blood glucose reduction, with some stopping medication. The device mimics gastric bypass effects without surgery.